Vijay Vir Kakkar

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Thrombosis Research Institute, Trigen Gmbh. Active years: 1996-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vijay Vir Kakkar. Retrieved from https://idiyas.com/inventor/vijay-vir-kakkar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 49(Granted Patents)

Location History:

Hants, GB (2000)
Bickley, GB (1996 - 2002)
Warsash, GB (2002)
London, GB (2013 - 2022)

Company Filing History:

5 out of 10

Thrombosis Research Institute

Years Active: 1996-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11332515 - Multi-epitopic construct (2022-05-17),

2. 8435538 - Anti-atheroma vaccine (2013-05-07),

3. 6451976 - Bi-or multifunctional molecules based on a dendroaspin scaffold (2002-09-17),

4. 6387881 - Inhibitors and substrates of thrombin (2002-05-14),

5. 6127340 - Serine protease inhibitors (2000-10-03),

6. 5858979 - Inhibitors and substrates of thrombin (1999-01-12),

7. 5648338 - Inhibitors and substrates of thrombin (1997-07-15),

8. 5596123 - Boric ester synthesis (1997-01-21),

9. 5576304 - Antithrombotic composition (1996-11-19),

Title: The Innovative Contributions of Vijay Vir Kakkar

Introduction

Vijay Vir Kakkar is a notable inventor based in Bickley, GB. He has made significant contributions to the field of immunology, particularly in the development of vaccines and therapeutic constructs. With a total of 9 patents to his name, Kakkar's work has the potential to impact the treatment and prevention of atherosclerosis.

Latest Patents

Kakkar's latest patents include a Multi-epitopic construct, which relates to multiple epitope constructs and immunogenic compositions. These compositions comprise recombinant molecules that present inserted multiple and different epitopes from various antigens. The invention focuses on antigenic determinants associated with different pathways leading to atherosclerosis. It aims to elicit an immune response against antigens and pathogens involved in the disease's development. Additionally, the invention includes methods for treating and/or preventing atherosclerosis and recombinant protein products. Another significant patent is the Anti-atheroma vaccine, which comprises a recombinant protein featuring a carrier portion and two distinct epitopes capable of eliciting an anti-atheroma response.

Career Highlights

Throughout his career, Kakkar has worked with esteemed organizations such as the Thrombosis Research Institute and Trigen GmbH. His work in these institutions has allowed him to further his research and develop innovative solutions in the field of immunology.

Collaborations

Kakkar has collaborated with notable individuals in his field, including Michael Finbarr Scully and John Joseph Deadman. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Vijay Vir Kakkar's innovative contributions to immunology and his extensive patent portfolio highlight his dedication to advancing medical science. His work has the potential to significantly impact the treatment of atherosclerosis and improve patient outcomes.

Profile summary based on public USPTO records.